In the News: Vivasc Therapeutics Receives Its Second NIH Phase I STTR Grant

Our Aim

Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner.

We are actively seeking:

  1. Joint development partners for our lead compound, CTP-amio, for the treatment of arrhythmias (atrial fibrillation and ventricular tachycardia)
  2. Partners to use CTP as a platform vector to deliver other therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytes